ArticleJournal of the American Society of Nephrology : JASN2026
Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.
Article in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Baxdrostat in Resistant and Uncontrolled Hypertension: A Systematic Review and Meta-Analysis.Cardiovascular drugs and therapy · 2026Pooled it
- Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta-Analysis of Three Phase 2/3 Randomized Controlled Trials.Clinical cardiology · 2026Pooled it
- Baxdrostat: First Approval.Drugs · 2026Review
- Aldosterone Synthase Inhibitors: Emerging Therapeutic Strategies in Resistant Hypertension.Life (Basel, Switzerland) · 2026Review
- Autophagy and Mitophagy in Hypertensive Chronic Kidney Disease: Evidence Grading, Cell-Type Divergence, and a Working Lysosomal Hypothesis.Life (Basel, Switzerland) · 2026Review
- Aldosterone synthase inhibitors for the treatment of cardiovascular disease.Nature reviews. Endocrinology · 2026Review
- Comparative Efficacy of Aldosterone-Related Sodium-Retention Pathway Therapies for Resistant Hypertension: A Drug-Level Network Meta-Analysis of Randomized Controlled Trials.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Can baxdrostat redefine blood pressure control in resistant and uncontrolled hypertension? a systematic review, meta-analysis, and trial sequential analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Aldosterone Synthase Inhibition in Diabetes and Cardiorenal Metabolic Disease.Journal of diabetes · 2026Article
- Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status.Kidney international reports · 2026Article
- Aldosterone in Diabetic Kidney Disease: From Mineralocorticoid Receptor Antagonism to Aldosterone Synthase Inhibition.International journal of molecular sciences · 2026Review
- Combined Aldosterone Synthase and SGLT2 Inhibition: A Recipe for Success in CKD with Uncontrolled Blood Pressure?Current hypertension reports · 2026Review
- CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.Cardiovascular diabetology · 2026Article
- Emerging Medical Therapies for Primary Aldosteronism.Hypertension (Dallas, Tex. : 1979) · 2026Review
- The evolving field of nephrology: what comes next? A report from the European Renal Association Scientific Advisory Board.Clinical kidney journal · 2026Review
- Review
- Emergence of aldosterone synthase inhibitors for treatment of difficult to treat hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Second-Generation Aldosterone Synthase Inhibitors for Hypertension: A Bayesian Meta-Analysis of Randomized Trials.JACC. Advances · 2026Article
- Baxdrostat and Other Aldosterone Synthase Inhibitors for Uncontrolled Hypertension in CKD: A Long-Awaited New Option?Journal of the American Society of Nephrology : JASN · 2026Article
- Residual risk in cardiovascular and renal diseases and the potential role of aldosterone synthase inhibitors.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.